FDCDDQ
ONCY

Federation des caisses Desjardins du Quebec’s Oncolytics Biotech ONCY Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$31K Buy
36,499
+4,600
+14% +$4.58K ﹤0.01% 1989
2025
Q4 		$27.9K Hold
31,899
– – ﹤0.01% 1971
2025
Q3 		$44.7K Sell
31,899
-3,895
-11% -$4.36K ﹤0.01% 1837
2025
Q2 		$26.8K Buy
35,794
+20,000
+127% +$10.6K ﹤0.01% 1727
2025
Q1 		$8.67K Sell
15,794
-2
-0% -$1 ﹤0.01% 2007
2024
Q4 		$14.4K Hold
15,796
– – ﹤0.01% 1764
2024
Q3 		$13.9K Buy
15,796
+2,502
+19% +$2.46K ﹤0.01% 1777
2024
Q2 		$13.1K Buy
13,294
+10,000
+304% +$10.9K ﹤0.01% 1733
2024
Q1 		$4.68K Hold
3,294
– – ﹤0.01% 1976
2023
Q4 		$4.36K Sell
3,294
-736
-18% -$1.15K ﹤0.01% 1933
2023
Q3 		$8.66K Buy
4,030
+1,491
+59% +$3.64K ﹤0.01% 1805
2023
Q2 		$6.52K Sell
2,539
-2,105
-45% -$3.5K ﹤0.01% 1853
2023
Q1 		$5.56K Sell
4,644
-1,263
-21% -$1.98K ﹤0.01% 1884
2022
Q4 		$9.56K Sell
5,907
-2,000
-25% -$3.04K ﹤0.01% 1886
2022
Q3 		$9.81K Buy
7,907
+4,000
+102% +$4.9K ﹤0.01% 1922
2022
Q2 		$3.76K Buy
3,907
+500
+15% +$608 ﹤0.01% 2196
2022
Q1 		$5.38K Hold
3,407
– – ﹤0.01% 2180
2021
Q4 		$4.71K Hold
3,407
– – ﹤0.01% 2215
2021
Q3 		$6.95K Hold
3,407
– – ﹤0.01% 2154
2021
Q2 		$9.34K Sell
3,407
-5,263
-61% -$16.1K ﹤0.01% 2070
2021
Q1 		$32.5K Sell
8,670
-7,715
-47% -$23K ﹤0.01% 1672
2020
Q4 		$38.5K Sell
16,385
-4,000
-20% -$9.58K ﹤0.01% 1569
2020
Q3 		$34.6K Buy
20,385
+3,300
+19% +$6.05K ﹤0.01% 1341
2020
Q2 		$32.2K Buy
17,085
+9,000
+111% +$16.9K ﹤0.01% 1325
2020
Q1 		$11.2K Sell
8,085
-7,600
-48% -$19K ﹤0.01% 1644
2019
Q4 		$74.3K Buy
15,685
+7,700
+96% +$8.69K ﹤0.01% 1399
2019
Q3 		$4.58K Hold
7,985
– – ﹤0.01% 1975
2019
Q2 		$13.8K Hold
7,985
– – ﹤0.01% 1771
2019
Q1 		$14.6K Hold
7,985
– – ﹤0.01% 1581
2018
Q4 		$14.3K Hold
7,985
– – ﹤0.01% 1552
2018
Q3 		$30.6K Hold
7,985
– – ﹤0.01% 1458
2018
Q2 		$42.8K Buy
+7,985
New +$49.2K ﹤0.01% 1388

Other funds holding ONCY

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SFP
Sandbox Financial Partners Bethesda, Maryland $356M AUM 19.83% 1-Year Est. Return
SI
Seeds Investor New York $735M AUM 17.54% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $442M AUM 34.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's ONCY Position: Q1 2026 in Review

Federation des caisses Desjardins du Quebec increased its Oncolytics Biotech (ONCY) stake by 14% in Q1 2026, buying an estimated $4.58K and bringing the position to 36,499 shares worth $31K. The position accounts for ﹤0.01% of the portfolio, ranked #1989.

Federation des caisses Desjardins du Quebec first reported a position in ONCY in Q2 2018 and has held it in 32 quarters since. The position peaked at $74.3K in Q4 2019. 59 funds tracked by Wall St. Rank hold ONCY as of Q1 2026.

  • Federation des caisses Desjardins du Quebec held 36,499 shares of Oncolytics Biotech worth $31K as of Q1 2026.
  • Federation des caisses Desjardins du Quebec bought 4,600 Oncolytics Biotech shares in Q1 2026, an estimated $4.58K.
  • Oncolytics Biotech made up ﹤0.01% of Federation des caisses Desjardins du Quebec's portfolio in Q1 2026, its #1989 holding.
  • Federation des caisses Desjardins du Quebec first reported a position in Oncolytics Biotech in Q2 2018 and has held it in 32 quarters since.
  • Federation des caisses Desjardins du Quebec's Oncolytics Biotech position peaked at $74.3K in Q4 2019.
  • 59 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q1 2026.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q1 2026, filed 14 May 2026.